However, the course of metastatic melanoma treatment has changed markedly since the introduction of the immune checkpoint inhibitors designed against either cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or Programmed death receptor-1 (PD-1), both negative regulators of T-cell immune function [153]. This evidence concerns the gene CTLA4 and metastatic melanoma.